FOSUN PHARMA - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

make any statement and expressly disclaim any liability for any damages whatsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

assumes no responsibility for any failure.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 02196)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to set forth the "2025 Annual Report" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange.

Annual Environmental, Social and Governance (ESG) and Sustainability Report" is for reference only.

By order of the board of directors Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Chairman

Chen Yuqing

China, Shanghai

March 24, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the Company The non-executive directors of the company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the company are Mr. Yu Zishan, Mr. Wang Quandi, and Mr. Chen Mr. Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

*For identification only

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Continued

newspaper Environmental, Social and Governance (ESG) and Sustainability in 2025 develop sue Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Address: Building A, No. 1289 Yishan Road, Shanghai Environmental, Social and Governance (ESG) 2025 Tel: (86 21) 3398 7000 Fax: (86 21) 3398 7020 and Sustainability Report Website: www.fosunpharma.com Official WeChat public account Official WeChat video account Postcode: 200233

Directory ................................................................. 01 Directory .................................................... 02 Chairman's speech ................................................. 04 About this report ................................................. 06 About Fosun Pharma 2025........................................08 Major Company Events in Years (SDGs) ........................ 10 United Nations Sustainable Development Goals Table of Contents 1 4 Corporate Governance Win-Win Cooperation 1.1 12 4.1 98 Corporate Governance Supplier Management 1.2 22 4.2 102 Risk management and sustainable supply chain 1.3 24 4.3 105 Business Ethics Association Membership 1.4 35 information security and Privacy protection 2 5 Product Responsibility Focus on Talent 2.1 39 5.1 106 Innovative R&D, Diversity and Equal Opportunities 2.2 46 5.2 116 Quality Management Human Capital Development 5.3 125 Occupational Health and Safety 3 6 Environmental Protection Social Contribution

3.1 61 6.1 135 Addressing climate change and providing inclusive healthcare 3.2 78 6.2 144 Environmental Management Community Care 3.3 95 6.3 146 Circular economy rural revitalization 3.4 97 ecosystems and organisms diversity protection ................................................. 148 Third-party assurance report GRI........................150 Appendix 1 Content Index of "Sustainability Report"

Appendix 2 "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. ............................154 Sustainability Report (Trial)》Content Index ........ 155 Appendix 3 Content Index of the Hong Kong Stock Exchange’s Environmental, Social and Governance Reporting Code . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166 Appendix 4 Key Performance Indicators Table ................................................................. 172 Definition

Chairman's speech

Chen Yuqing Chairman of Fosun Pharma

2025 In 2018, the global pharmaceutical industry was forging ahead amidst changes. Fosun Pharma began to draw a new picture of low-carbon development based on green. We always adhere to the original intention of "let every family enjoy health" and adhere to "innovation-led, AI The strategy of "deep internationalization and comprehensive embrace", focusing on innovation and deeply cultivating the common green homeland of mankind is a must-answer for corporate development. us The world is moving forward steadily on the road of high-quality development, and it actively responds to the national "double carbon" goals in terms of environment and society, and continues to improve the environmental management system so that ESG 2025 In the practice of management and governance ( ), we have delivered an answer full of warmth and strength. Green operations are integrated into every aspect of production and operation. year, we communicate MSCI ESG AA Volume. This year, our rating jumped to A-level. Hang Seng has upgraded environmental protection facilities, expanded its own photovoltaic power generation scale, and improved green power procurement. ESG A – 2025 ESG The rating has been maintained at level 1, and it has been selected as "Fortune China" to influence purchase ratio and other diversified measures to continue to reduce carbon emissions and comprehensive energy consumption. 2025 8,000 "Strength List", becoming the only Chinese pharmaceutical company on this list. In this industry, the Group invested nearly RMB 10,000 in environmental protection every year. Leading recognition is an affirmation of our persistence in sustainable development, and it is also a sign that we will continue to make progress on the road to environmental protection and fulfill our low-carbon responsibilities with every action. They have the confidence to go on a longer journey. Ren, and contribute to the green transformation of the pharmaceutical industry.

02 Innovation for Good Health Continuous innovation and enjoyment of health

Chairman's speech

With innovation as the core, we protect the accessibility of global health. With responsibility in mind, we practice our social responsibilities and warm people's hearts.

Innovation is one of Fosun Pharma's most important social responsibilities. We focus on the future. The background of the pharmaceutical industry is the temperature that protects life. We respond positively To meet clinical needs, focus on tumors, immune inflammation, and neurodegenerative diseases, "Healthy China" and rural revitalization strategies, and protect health with responsibility. As of reporting ADC 16 By the end of the period, Fosun Charity Foundation’s “Rural Doctor” project has covered 78 2.5 Treatment and other core technology platforms, and actively expand nuclear medicine, small nucleic acid and other cutting-edge counties, provinces, municipalities and autonomous regions to assist counties, a total of 10,000 people have been protected 300 2025 technology, strengthen early innovation capabilities, accelerate the transformation of scientific research results, and enable innovative rural doctors to benefit tens of thousands of rural families. In 1999, a rural doctor The results truly benefit more patients around the world. The project "Star Guardian Famous Doctors' Grassroots Tour" entered Zhejiang, Yunnan, Sichuan, and Jiangxi We have carried out in-depth health assistance in many rural areas and injected vitality into primary care. 2025 4 In 2019, the self-developed small molecule innovative drug Fumaining was approved for dual indications. In the past three years, the Group’s total charity donations have exceeded RMB 100 million. market, giving Chinese patients with rare tumors new hope for treatment. As of 2025 10 At the end of the year, Fuhong Hanlin, its holding subsidiary, had 2 products approved for listing. Based on governance, we will build a solid ballast for steady development.

market, benefiting more than 10,000 patients worldwide. Among them, the Hansi shape is the first in the world PD-1 The anti-monoclonal antibody approved for first-line treatment of small cell lung cancer has filled the gap. High-quality development is inseparable from a sound governance structure. The Group has ESG There has been a clinical blank in this field for decades, and it has been included in the management performance appraisal scope in China, the European Union, and the United Kingdom to allow sustainable development. 40 2025 12 It has been approved by more than 10 countries and regions including China and India. In the year and month, communication is deeply integrated with business operations and resonates with the same frequency. We always adhere to compliance By signing an investment agreement, we plan to acquire a controlling stake in Green Valley Pharmaceuticals to integrate its core production lines, continue to strengthen integrity construction, improve the risk prevention and control system, and improve information security. Pinganluate Sodium Capsules are included in the innovation pipeline; management is strictly enforced in the fields of global public health and business ethics, with a view to serving the enterprise through standardized operations. 8,800 In this field, our injectable artesunate has saved more than 10,000 patients and protected the long-term development of the industry. Malaria patients, the main structure of the first phase of the Ivory Coast park was successfully capped 5 ESG It has obtained a local production license, with a designed production capacity of 100 million tablets per year in the first phase. In the future, Fosun Pharma will continue to practice its philosophy and innovate more firmly. Lay a solid foundation for localized pharmaceutical manufacturing in Africa. pace, more solid green practices, and deeper social responsibility to protect Taking life and health as our own responsibility, we work together with global partners to realize "let every family We will continue to strive for the mission of "Enjoy Health" and provide high-quality products for the global pharmaceutical industry. Contribute to China’s development!

2025 Environmental, Social and Governance (ESG) and Sustainability Report

About this report

ESG As the international and domestic society's understanding of corporate sustainable development increases, the capital market and the public's understanding of social responsibility are gradually unified. for Respond more comprehensively to the concerns of the capital market and the public on corporate sustainable development, improve the readability of the report and the consistency of the information, and specifically disclose this report.

Compilation basis

This report complies with the Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. Sustainability Report (Trial) and the Hong Kong Stock Exchange C2 GRI Ltd.'s Securities Listing Rules" appendix "Environmental, Social and Governance Reporting Code" and refer to the "Sustainability Reporting Standards". At the same time, ESG MSCI ESG In order to respond to investors' concerns about the Group, this report refers to and corresponds to the issues of concern in the rating. In addition, this report also CSR Covers all corporate social responsibility ( ) related content for shareholders to obtain more detailed information about the Group’s social responsibility and sustainable development information. The financial data involved in this report are prepared in accordance with the Chinese Accounting Standards for Business Enterprises. Report scope and boundaries 2025 The disclosure scope of this report is consistent with the disclosure scope of the Group’s financial information in its annual report. 2025 1 1 2025 12 31 The time period covered by this report is from year month day to year month day.

Data source and reliability guarantee

The information and cases in this report mainly come from the Group's official documents, statistical reports and financial reports. The Group promises that this report does not contain any false records. contains, misleading statements, and is responsible for the authenticity, accuracy and completeness of its content.

Confirm and approve

2026 3 24 This report was approved by the board of directors on day, month, year.

04 Innovation for Good Health Continuous innovation and enjoyment of health

About this report

Obtain and respond to this report https://www.fosunpharma.com Based on environmental protection considerations, we recommend reading the electronic version of the report, which can be found on the company’s official website Get.

Readers are welcome to contact us through the following contact information. Your opinions will help us further improve this report and improve our overall sustainability performance.

Contact information

[email protected] Email: 1289A Address: Building No. Yishan Road, Shanghai

2025 Environmental, Social and Governance (ESG) and Sustainability Report

About Fosun Pharma

600196.SH 02196.HK 1994 Fosun Pharma (stock code: ; ) was founded in 2016 and is an innovation-driven global pharmaceutical and health industry group. We use With the mission of "let every family enjoy health", we are deeply involved in the pharmaceutical business, focusing on innovative drugs, and directly operating medical devices, medical diagnosis, and medical health care. Healthcare service business, and at the same time covering the pharmaceutical business field through the associated company Sinopharm Holdings, building an ecosystem of the entire pharmaceutical and health industry chain.

Focus on innovation and deepen global expansion. Fosun Pharma has formed an open and global innovative R&D system, focusing on unmet clinical needs, with in-depth layout in oncology, We will focus on core treatment areas such as immune inflammation and neurodegenerative diseases, actively expand treatment areas such as chronic diseases and rare diseases, and gradually build a long-term competitive product portfolio. ADC Quality pipeline and comprehensive solutions. At the same time, Fosun Pharma continues to consolidate core technology platforms such as antibodies and drugs, small molecules, and cell therapy, and actively expands

In the direction of cutting-edge technologies such as nuclear drugs and small nucleic acids, we will strengthen early innovation capabilities and accelerate the transformation of scientific research results. Our innovative products have been used in many countries and Regional sales cover markets such as China, the United States, Europe, Africa, India and Southeast Asia. AI Facing the future, under the strategic guidance of "innovation-led, in-depth internationalization, and comprehensive embrace", Fosun Pharma will adhere to the principles of "caring for life, continuous innovation, and leanness". With the core values of "pursuing excellence and win-win cooperation", we are committed to becoming the world's leading integrator of medical innovation and striving to promote medical innovation results to benefit more people around the world. Patients contribute to protecting human health. www.fosunpharma.com For more information about the Group, please log on to the company's website: .

06 Innovation for Good Health Continuous innovation and enjoyment of health

About Fosun Pharma

AI Strategic keywords: innovation leadership, in-depth internationalization, comprehensive embrace

Cultivate blockbuster products

Fully embrace AI

Sustainable Development Goals: ESG Fosun Pharma Group practices and deepens the concept of sustainable development and fully integrates it into the company's daily operations and management practices. We insist on deeply cultivating medicine The health industry uses innovation to drive global health accessibility and is committed to becoming a pharmaceutical and health industry group with global influence in the field of sustainable development and serving people Contribute solidly to human health and social development.

2025 Environmental, Social and Governance (ESG) and Sustainability Report

2025 Major Company Events in Years

• Abbott • • Announced that it will once again cooperate with 2 independently developed H etrs on Ruifly® monoclonal antibody injection (European (European C) formal Pharm AID released independently developed Hands-on, a number of biopharmaceuticals under the trade name: ) have been approved by the European Commission as decision-making intelligence agents Approved in Asia, Latin America and Canada, combined with carboplatin and etoposide for use in a broad platform, building a coverage innovation ES-SCLC The full life cycle of a research and development scenario for adult patients with stage small cell lung cancer ( ) in the Caribbean and the Middle East and North Africa.

It has reached online treatment in an emerging market and became the first phase-out intelligent decision-making network approved for marketing in the EU. PD-1 External licensing cooperation. Resistance to treatment of extensive-stage small cell lung cancer •

monoclonal antibodies. Innovative phosphorus-lowering drugs made with brand new machine Ventilex (Tenapanol Hydrochloride) • PD-L1 (ADC) HLX43 Targeted antibody conjugate drug tablets) were approved by the State Food and Drug Administration • ESG Star Pharmaceuticals has been listed on the list of "China's launch of (ESC in C) for the treatment of recurrent/metastatic esophageal squamous cell carcinoma." The phase II clinical study of the listed company 0 (company 202 Ke 4) Technology Innovation was completed in China 5 • "New Pioneer" became the first 43 patients to receive HLX. By the end of the year, Nanning Pharmaceutical and Equipment Sales Platform was newly established. Single, this list is compiled by the Central Radio and Television Station for the treatment of stage II advanced non-small cell lung cancer, and gradually promotes attention in Southeast Asia. The Joint Affairs Bureau of China Broadcasting and Television Station has obtained registration and commercialization capacity building for clinical research in China, the United States, Japan and Australia. Clinical trials have been approved by the State-owned Assets Supervision and Administration Commission of the hospital and the National Industry and Commerce Bureau, and have been completed for the first time in China and the United States. Jointly administered by the Chinese Academy of Social Sciences and the Chinese Academy of Social Sciences. Economic Research Think Tank, China Corporate Reform and Development Research • Fakeeh Care Group Will wait for the authoritative agency to launch it. Reach war with Saudi Arabia 3 4 Strategic Cooperation C Cooperation AR, -T will jointly promote including biological drugs, cell therapy, and many other The launch of leading therapies in Saudi Arabia. 1 2 3 4 5 6 7 Month Month Month Month Month Month • 2025 ESG • Teva FXB0871 PD-1 5 Selected into Fortune China’s Influence List 6 and IL-2 ( single, becoming the only targeted fusion protein selected into the list this year) Chinese pharmaceutical companies. Joint development reaches strategic agreement , To further strengthen the tumor • 2025 AI Fosun Pharma was selected into Forbes China's "Layout in the Immunotherapy Field." Top "Innovative Scenario Application Enterprises" list. • Recombinant humanized anti-human epidermal growth factor receptor 2(HER2) HLX22 Monoclonal antibody for gastric cancer treatment Orphan drug designation granted by the European Commission, Becoming the first company in the world to obtain both EU and U.S. HER2 Gastric cancer anti-target with orphan drug designation therapy. • ® The independently developed innovative drug Futuoning (citrate Vovesicil Capsules) were approved by the State Food and Drug Administration On the market, the indication is combined with fulvestrant for Treatment of disease developed after previous endocrine therapy 7 (HR) HER2 • MSCI ESG Hormone receptor positive in disease progression, Fosun Pharma's rating jumps AA Negative for recurrent or metastatic breast cancer. To , ranking first in the domestic industry. • MEK ® • The self-developed inhibitor Fumainin (Lu Fosun Pharmaceutical) has been listed on Deloitte’s list for three consecutive years. Wometinib Tablets) was awarded "China Excellent Management Company" by the National Food and Drug Administration for dual indications. FDA approves marketing to fill the gap in rare tumor treatment • demand. License introduction to delay Alzheimer’s disease Orally administered small molecules for silent disease progression AR1001 Drugs. 08 Innovation for Good Health Continuous innovation and enjoyment of health

• DPP–1 8 F to XS 75 Xu 53 Oral small molecule (Original project code: ). signed with • strategic cooperation agreement, both parties will The first domestically developed COVID-19 A- and B-fluidic antibody independently developed around "vertical particle therapy" Original test kit (colloidal gold method), and independent research and development of indoor system" in China Commercialization of novel coronavirus A and B nucleic acid detection kits (fluorine and Macau, China) PCR light method) have been approved for marketing by the State Food and Drug Administration. Implement in-depth collaboration. • ® SFDA • Fumaining (ruwometinib tablets) was awarded the independently developed primaquine phosphate by the Saudi Food and Drug Administration ( ) LCH Breakthrough therapy designation for the treatment of Langerhans cell histiocytosis ( ) and dispersible tablets were officially approved PQ Indications in adult patients with histiocytic neoplasms. Certified, it is the first PQ Certified Phosphorus • FXS6837 Externally licensed and containing primaquine acid dispersible tablet preparations. products with this active ingredient. • 1AC-201 permission import() numerator, 2AC-201 and () any molecule containing Drugs with active ingredients, abundant Autonomous pipeline layout. • Independent B research and ILD development Y's OS Di® Shu B mono ILP anti REV injection DA® FDA Cumshot and are approved for sale in the United States. As of the end of the reporting period, The two biosimilar drugs have been successively approved in the United States, the European Union, and the United Kingdom. 8 9 10 11 12 month month month month month • 2025 9 10 Multiple drugs were successfully included in the national medical insurance in 2012 Directory, including: 2025 Newly included in the National Medical Insurance Directory: Fumaining® (ruwometinib tablets) Futuoning® (vovisil citrate capsules) Ogenin® (Perampanel Oral Suspension) • Targeting PD-L1 Antibody drug conjugate Ventile® (Tenapanol Hydrochloride Tablets) • ® (ADC)HLX43 Suprathymic Prenil (Prutomanid Tablets) Futuoning (vovisicil citrate gum (TETs) The drug registration application for new indications has been successfully renewed by the FDA for oncology treatment in the United States: Please obtain approval from the State Food and Drug Administration for this new orphan drug qualification, Besun® (Caprasen Hydrochloride Tablets) The indication was expanded to be used for hormone receptors, becoming the world's first AD intended to be used in C-chest Peijin (Topfilgrastim Injection) Treatment of HR glandular epithelial tumors. ( ) positive, human epidermal growth factor Receptor 2 (HER2 ) negative locally advanced or • (Helsinn) The first batch of products included in the first edition of the Commercial Insurance Innovative Drug Catalog: Cooperate with Helsin Group to reach Yikaida (Akilonsai Injection) Adult patients with metastatic breast cancer: vs. Into the antiemetic drug Nepitatam • Awarded to Pfizer for the combined use of aromatase inhibitors as an oral drug independently developed and with independent intellectual property rights Lonosetron concentrated solution for injection -1 GLP-1R for initial endocrine therapy. Molecular glucagon-like peptide receptor ( ) agonists (including Strategic cooperation for localized production. YP05002 ) and products containing this active ingredient are exclusively available worldwide • CAR-T The development, use, production and commercialization rights of the second product Brickiolan. The drug registration application for Sai injection was approved by the country • Accepted by the National Food and Drug Administration, indication B is a new indication for the independently developed slulimumab injection (P is D-combination L1 combination Neoadjuvant platinum-containing chemotherapy for relapsed or refractory precursor cells, adjuvant treatment after surgery, for positive Treatment of Adult Patients with ALL. The drug registration application for patients with sexual, surgically resectable gastric cancer) was approved The State Food and Drug Administration accepted the application and has been included in the priority review process. • Nuclear medicine platform Xingrui Jingxuan was established in Sichuan • Signed an investment agreement to acquire a controlling stake in Green Valley Pharmaceuticals, with a view to converting its core All were officially unveiled. The drug mannate sodium capsule has been included in the Group's innovative drug pipeline. • • Aditum Bio Fosun Pharma has reached a strategic cooperation with its affiliated funds to jointly promote the development of innovative drugs Launched for dual indications, to fill in rare cases. Development of selected target compounds. Blank in the Treatment of Tumor Diseases", honored 2025 "Tell good medical stories in the new era" Best case scenario.

2025 Environmental, Social and Governance (ESG) and Sustainability Report

SDGs

United Nations Sustainable Development Goals ( ) Table of Contents

SDGs 2025 year progress • 5 As of the date of this report, the Group has been approved for rare disease indications and has rare disease indications under research.

Recent items • 90 WHO During the reporting period, 10,000 people donated to Angola, Tanzania, Kenya and other African countries. PQ Certified malaria prevention and treatment drugs to help Africa fight malaria • Through strict internal price management and dynamic adjustment mechanisms, we ensure that drug pricing is consistent across the country. Fairness and transparency, effectively reducing the burden of medication on patients • GDP In the international market, we base our decisions on the levels of different countries and different regions of the same country, as well as the United Nations development index, national health budget, patient needs and affordability, and other related health economics Consider factors and implement differentiated pricing strategies aimed at aligning drug prices with local economic conditions and medical needs. to improve the accessibility of medicines in developing countries and emerging markets • 2025 16 We continued to be deeply involved in the “Rural Doctor” project. By the end of the year, the project had covered 10 provinces, municipalities, and autonomous regions. 78 2.5 300 A key assistance county in the district, protecting 10,000 rural doctors and benefiting 10,000 rural families • EHS IT For employees in different departments, including quality, , lean management, , R&D, production, marketing, and finance Provide employees with position-related customized course training to meet the development needs of other business departments. • Established academic qualification improvement and professional qualification certification programs for all employees, such as on-the-job graduate training programs • Formulate an "Employee Diversity Policy" to protect employees from race, skin, etc. in terms of job application, salary, promotion, etc. color, gender, religion, nationality, disability, marital status, veteran status, sexual orientation, gender identity or Impact of Other Legally Protected Identities • During the reporting period, the “Women’s Day Sharing by Female Employee Representatives” event was held, inviting many female employees within the group to Work representatives communicated around career growth and industry insights, demonstrating the roles of women in R&D, production, operations, and marketing. Contribution and strength in fields such as fields • 2025 2025 Annual water consumption, wastewater and chemical oxygen demand did not exceed the annual emission target value • 2025 39.1 4% The total annual water saving achieved is approximately 10,000 cubic meters, accounting for 10% of the total annual water consumption. • Under the guidance of the energy conservation and carbon reduction policy framework, we encourage and support all holding subsidiaries to build solar photovoltaic power stations. station, integrating renewable energy applications into daily production operations and promoting green development • 3,137 2.15 During the reporting period, the Group’s total photovoltaic power output was approximately more than 10,000 kilowatt-hours, which was three times the photovoltaic power output of the previous year, corresponding to 1,654 COe 4,570

Carbon reduction tons; the total purchase of green electricity during the same period was more than 10,000 kilowatt hours, of which new energy power was purchased from external sources. 3,656 914 More than 10,000 kWh, purchased water and electricity more than 10,000 kWh

10 Innovation for Good Health Continuous innovation and enjoyment of health

SDGs United Nations Sustainable Development Goals ( ) Table of Contents

SDGs 2025 year progress • Provide employees with comprehensive training support and clear career development guidelines to ensure fair and diverse opportunities ization to reduce employee turnover • Committed to building and maintaining a diverse and inclusive working environment, and constantly paving career development paths for female employees • Encourage the creation of flexible jobs, protect the legitimate rights and interests of all employees, and promote common development • ADC Strengthen core technology platforms such as antibodies and drugs, small molecules, and cell therapy to create an open, global, and An efficient and complete "end-to-end" R&D system that runs through project establishment, early stage research and clinical trials to continuously enhance the value of the pipeline • 24 Establish an hourly global R&D center to continuously improve R&D and innovation capabilities • The Cote d'Ivoire park is located in the Grand Bassam area. After completion, it will have localized production capabilities; Create more jobs for the local area, effectively promote the development of the regional pharmaceutical industry, and help improve the region’s reputation in the West Industrial status and influence in non-regional medicine and health fields • EHS Set up a five-year strategy covering "three wastes" (waste gas, waste water, waste) management and water resources management, and promote Effective management and continuous optimization of the animal environment, with multiple environmental indicators exceeding phased targets • Update the "Supplier Code of Conduct" to clarify the management responsibilities that first-tier suppliers need to bear, and conduct regular audits. Ensure compliance with the quality and safety requirements of the Group’s products and services • TCFD RCP2.6 RCP8.5 NZE With reference to the (Task Force on Climate-related Financial Information Disclosure) framework, we adopt , , , STEPS Analyze four climate change scenarios to identify the climate change risks faced by enterprises and formulate adaptation and Mitigation strategies • EHS In order to respond to climate-related risks and opportunities, we proactively established a five-year strategic plan to integrate energy conservation and reduction Emissions, energy management and other core issues should be deeply integrated into the climate change strategy and regarded as a top priority • 1,647.13 40.25 During the reporting period, the Group saved a total of 10,000 kWh of electricity, 10,000 cubic meters of natural gas, and 10,000 cubic meters of purchased steam. 6,737.69 11,811 COe 1.717GJ/

tons, the corresponding carbon reduction amount is tons, and the comprehensive energy consumption intensity is RMB 10,000 6.8% Closed, down year-on-year • 2025 Annual carbon emission intensity and energy-saving project carbon reduction targets have been achieved • – – – – Continue to improve the anti-corruption compliance management system of "prevention, monitoring and punishment" (i.e. prevention, monitoring and remediation), and continue to strengthen Improve anti-corruption supervision • Regularly conduct business ethics and anti-corruption training for all employees of the Group • Carry out special training covering the safety of the national medical insurance fund covering all employees • Organized the "Third Compliance Culture Week" event to deepen employees' awareness of compliance

2025 Environmental, Social and Governance (ESG) and Sustainability Report

corporate governance

The Group adheres to integrity in its operations. We firmly believe that sound governance, perfect compliance and efficient management are conducive to the steady development of enterprises and enhance their resilience. 2025 Society continues to create value. In 2018, we continued to improve corporate governance, abide by business ethics, and enhance operations through continuous improvement of the risk management system. Stability. In terms of cooperation with stakeholders, we establish efficient communication channels and establish a responsible corporate brand image. We are committed to creating a public Create a transparent, harmonious and friendly business ecosystem and work hand in hand with all stakeholders. 1.1 corporate governance Corporate governance has a vital impact on the sustainable development of enterprises. In order to enhance corporate value and increase investors and stakeholders’ confidence in the company Trust, we are committed to establishing a transparent, accountable and effective governance mechanism. Fosun Pharma complies with the China Securities Regulatory Commission's "Code of Corporate Governance for Listed Companies" and Hong Kong's The "Corporate Governance Code" of the Hong Kong Stock Exchange requires continuous improvement of the corporate governance structure system to effectively ensure scientific and efficient governance decision-making.

1.1.1 Professional diversity The cornerstone of efficient operations lies in a sound governance structure. Fosun Pharma’s governance structure consists of the shareholders’ meeting, the board of directors and the management.

Clear, clear rights and responsibilities. Among them, the board of directors has several special committees, namely Strategy Committee, Audit Committee, Nomination Committee, ESG Compensation and Appraisal Committee and Committee. Special committees perform their respective duties and conduct comprehensive supervision of matters in different fields to ensure that the enterprise The industry can maintain stable, compliant and efficient operations. The company has established a special meeting mechanism for independent non-executive directors to build a It provides a platform for directors to perform their duties, actively leverages the professional expertise and advantages of independent non-executive directors, and promotes the company's standardized operations and scientific decision-making. Fosun Medical Pharmaceutical independent non-executive directors play the role of "participating in decision-making, supervising checks and balances, and providing professional consultation" and exercise their powers independently and objectively. On the board of directors and various professionals Under the supervision and guidance of the department committee, the Group maintains high-level governance standards, actively safeguards the legitimate rights and interests of all stakeholders, and Continuously strive to enhance corporate value. Fosun Pharma complies with the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the China Securities Regulatory Commission's Code of Governance for Listed Companies, The Hong Kong Stock Exchange's "Corporate Governance Code" and other laws and regulations continue to improve the governance structure and its operating mechanism to ensure standardized and efficient operation. newspaper 2024 7 During the reporting period, the company complied with the "Company Law of the People's Republic of China" (the "New Company Law") that came into effect in March 2019 and the provisions issued by the China Securities Regulatory Commission. The "Transitional Arrangements Related to the Implementation of Supporting Institutions and Rules of the New Company Law" and the "Guidelines on the Articles of Association of Listed Companies" and other relevant provisions have been completed to complete the

Revised multiple governance documents, including the Articles of Association, to match the latest governance framework of listed companies; and completed the orderly completion of the employee board of directors in the same period election of directors and the reelection of the board of directors and management to ensure a smooth transition of the governance mechanism, including: canceling the board of supervisors and appointing the audit committee of the board of directors We will exercise the powers of the board of supervisors stipulated in the new Company Law and add employee directors to ensure that employees enjoy full rights in corporate governance. As the core decision-making body, the diversity of board members helps the Group cope with the changing business environment and safeguard the interests of the general public. Interests of Related Parties. To this end, the company has formulated the "Board Member Diversity Policy". During the selection process of board members, the policy clearly It requires comprehensive evaluation from multiple perspectives such as gender, age, cultural and educational background, professional experience, skill level, knowledge reserve and service tenure. All forms of discrimination are prohibited to ensure the integrity and fairness of the electoral process. At the same time, every year, the Nomination Committee of the Board of Directors The Board of Directors will review and evaluate the structure, size and composition of the Board of Directors, and make corresponding recommendations on any changes to the Board of Directors to ensure that Diversity policies can be effectively implemented.

12 Innovation for Good Health Continuous innovation and enjoyment of health

corporate governance

12 2 As of the end of the reporting period, Fosun Pharma’s Board of Directors consisted of directors, including female directors. An analysis of the diversity of board members is listed below As follows:

Employees (1 director)

(Female 2) years old (and above) PhD (Graduate 2) graduate student 10 independent Non-executive (executive) director

months and Take (6above)

55–64 (3) years old Master's degree (Graduate 6) 6 Non-executive (executive) directors ≥24 48 months ＜(1) month (1 male 0) 4 45–54 (7) years old

Execute (5 directors) matters within (5 months)

Studies (4 bachelors)

Gender Position Age Group Educational Qualifications Length of Service on the Board Board diversity data by gender, job title, age group, education, length of board service The members of the company's board of directors come from different industries and fields at home and abroad, with expertise in industry experience, business operations, finance, capital development and corporate governance, He has extensive experience in risk management, law and other professional fields closely related to sustainable development. Directors of the company are provided with sufficient resources to perform their duties, including seeking independent professional advice where appropriate; at the same time, board members continue to provide Improve capabilities to be competent for responsibilities. During the reporting period, the training received by board members included but was not limited to participating in the Shanghai Stock Exchange, Shanghai Listing Training organized by the Companies Association, reading regulatory and rule enforcement communications and press releases issued by the Hong Kong Stock Exchange, and participating in the company and legal advisory groups ESG Organizational training, etc., to provide a timely and comprehensive understanding of new regulatory developments such as corporate governance, risk management, etc. During the reporting period, each director participated in

The training duration shall not be less than hours. During the reporting period, members of the company’s board of directors actively participated in the “Director Practice” training organized by regulatory agencies such as the Shanghai Stock Exchange and the Association of Listed Companies. ESG training, including reading training materials, learning relevant information disclosure guidelines and management methods, and continuously improving our performance in sustainable development. 2025 level of knowledge and ability to perform duties. In 2019, the company’s independent non-executive directors also visited the companies in which it holds shares and gained an on-site understanding of the operations of the relevant companies. progress of business management, construction projects, innovative R&D projects, etc., and provide suggestions for corporate operations and future sustainable and healthy development. Your opinions and suggestions are appreciated.

2025 Environmental, Social and Governance (ESG) and Sustainability Report

corporate governance

1.1.2 ESG governance Sustainable development is one of the core elements of the Group's business development. We attach great importance to fully integrating the concept of sustainable development into strategy formulation and ESG major decision-making process, and continue to improve the governance system to strengthen supervision and execution. To this end, the Group has established a ESG ESG ESG A governance structure composed of committees, management committees and working groups to ensure that the board of directors and management can take a proactive approach to sustainable development Implement effective supervision, scientific guidance and resource support on relevant matters. The Group continues to implement the terms of reference of the Environmental, Social and Governance Committee of the Board of Directors. ESG Scope and Implementation Rules", clarifying the responsibilities, authority and working mechanism of the board committees. At the same time, we combine regulatory requirements and the Group’s ESG ESG ESG practice progress, continue to review and optimize the governance structure, further clarify the division of responsibilities at each level, and improve the systemic and The execution ability provides a solid guarantee for the orderly advancement of the Group's sustainable development work and continues to promote the improvement of overall sustainable development performance. ESG At the same time, the Group has incorporated the and sustainable development indicators into the management performance appraisal system, and the weight of the relevant indicators is no less than that of the overall performance. 10%ESG . The assessment content covers key dimensions such as the promotion and achievement of the carbon neutrality plan, the effectiveness of the management system construction, and is evaluated annually. Evaluation and review of results. The assessment results will be linked to the management's remuneration; if the relevant goals are not achieved, it will have a corresponding impact on their overall remuneration. To strengthen the implementation of responsibilities and promote the effective implementation of sustainable development goals.

14 Innovation for Good Health Continuous innovation and enjoyment of health

corporate governance

Level Organization Members Main Responsibilities ESG As of the end of the reporting period, the company’s Board of Directors is the highest decision-making body for the Group’s sustainable development and governance. 12 ESG The board of directors consists of 10 directors, who are responsible for the group's sustainable development performance and overall responsibility. 5 ESG ESG Including executive directors, the Board of Directors authorizes the Board of Directors Committee to carry out the sustainable development and matters of the Group. 2 4 ESG A non-executive director, responsible for supervision, guidance and review responsibilities of the Bank. Board committee responsibilities include, but do not Board of Directors Independent Non-executive Directors and Limited to: 1 (1) Employee directors formulate and adopt the Group’s environmental, social and governance vision, goals and strategies and structure, and provide the Board with relevant environmental, social and governance work suggestions; (2) Identification of significant impacts on the Group’s operations and/or the rights and interests of other important stakeholders decision-making level High-impact environmental, social and governance-related matters; As of the end of the reporting period, the Company (3) ESG examines the implementation of environmental, social and governance vision, strategy and structure; Board of Directors Committee consists of (4) ESG 5 Review the Group’s and sustainable development reports and propose specific measures or decisions directors, including ES Director G Committee Will

and 2 independent executive non-executive directors and executive directors. its matter Board of Directors Meeting ES, G Appoint personnel to serve as ES directors Will G things are considered every year until the next call. Hold 2 meetings to regularly listen to relevant information about the Group Report on sustainable development and matters, and submit relevant matters based on actual conditions , Director (Convenor) by ESG review by the board of directors; in addition, based on key issues, key matters, and regulatory rule updates serves as an independent non-executive director. ESG In response to new situations, the Board of Directors and the Board Committee also held corresponding temporary meetings to listen to Obtain relevant reports and/or review relevant matters. ESG The Management Committee is composed of directors. Responsibilities include but are not limited to: (1)ESG Chairman leadership, including assessment and management of relevant financial and impact material issues, including but not limited to Responsible for relevant business sectors, addressing climate change, carbon emissions, environmental management, quality management, innovative research and development, Management of functional departments Talent development, responsible marketing, supply chain management, social responsibility, inclusive medical care ESG treatment, corporate governance, etc., provide relevant analysis and suggestions, and make recommendations to the board of directors 2 ESG Reports to the committee and the board of directors (including regular reports once a year, and based on key Special reports on topics, key matters, rule updates, etc.); (2) ESG management and deployment are used to identify, mitigate, manage and monitor sustainability-related impacts. management Management impacts, risks and opportunities required costs and resources (including but not limited to budget, personnel committee strength, technology, etc.); (3) ESG ESG Organize, coordinate and guide the working group to carry out data collection and compilation ESG Prepare the Group and Sustainability Report; (4)ESG Review the Group’s relevant systems, norms, standards and other documents; (5)ESG Lead and supervise the working group to implement sustainable development policies and strategies. 2025 ESG 5 ESG In 2018, the Management Committee held a total of 1 meeting to listen to the working group’s opinions on possible ESG Report on sustainable development and related matters, discuss key issues, and unify Prepare and deploy promotion and improvement measures. ESG The working group is composed of various departments. Responsibilities include but are not limited to: (1) ESG ESG Relevant functional departments, lines and implement sustainable development policies and strategies to promote sustainable development and ESG 2 A dedicated person appointed by the business department will achieve the goals and report the progress to the management committee regularly, for at least one year 2025 5 It is composed of times and reported a total of times in a year; ESG (2) ESG Work Management Specific matters related to the issue, including identifying and assessing the impact of the issue Execution layer The team monitors impacts, risks and opportunities, completes data statistics and analysis, and formulates and implements improvement actions. Measures, tracking related implementation effects, etc.; (3)ESG Prepare the Group’s and sustainable development report; (4)ESG Drafting documents related to the Group’s systems, norms and standards; (5)ESG Enhance corporate brand image, etc.

2025 Environmental, Social and Governance (ESG) and Sustainability Report

corporate governance

board of directors decision-making level ESG Board of Directors Committee

ESG Management Management Board

ESG working group Execution layer Various functional departments Various business units ESG Fosun Pharma Management System ESG The Group continued to improve its management system and clarified the organizational structure and division of responsibilities of the decision-making, management and executive levels. During the reporting period, it strengthened ESG ESG Coordinate the management and collaborative promotion of relevant issues to ensure the effective execution and implementation of various tasks. ESG 2 2024 ESG 2025 During the reporting period, the Board of Directors Committee held a total of 3 meetings to review the Group’s annual and sustainable development report and the Group’s ESG ESG The plan for the year and sustainability reporting work was reviewed, covering sustainable development, strategies and goals and their implementation status. ESG status, list of substantive issues, communication with stakeholders, relevant work priorities, report preparation and other matters, and combine relevant matters with the actual situation. Matters are submitted to the Board of Directors for consideration. In addition, the Audit Committee of the Board of Directors receives reports on the implementation of the Group's business ethics standards every six months. Board Statement Board Responsibilities ESG ESG ESG ESG The Group has established a governance mechanism with the Board of Directors as the main body of responsibility, and has established Board committees, management committees and ESG Working groups form a multi-level governance structure covering decision-making, management and execution levels. The Board of Directors is the highest responsible body for the governance of the Group. ESG As an organization, it assumes the ultimate responsibility for the overall sustainable development performance of the Group and, with the assistance of the Board Committee, carries out the sustainability-related Supervise, guide and review work regularly. ESG ESG ESG The Board of Directors Committee provides advice and support to the Board of Directors to ensure that the philosophy is consistent with the Group’s strategic planning and to promote relevant Topics are fully integrated into the Group's strategic planning and major decision-making processes. In the strategic decision-making process, the Group systematically incorporates sustainable development related impacts, comprehensively consider risks and opportunities, and comprehensively assess the market environment when formulating long-term development plans and making major strategic choices. environment, business needs and sustainable development factors on the future development of the Group, and identify and evaluate possible environmental, social and Manage risks to enhance the foresight and resilience of strategic decision-making.

16 Innovation for Good Health Continuous innovation and enjoyment of health

corporate governance

Sustainability risk management ESG In order to effectively prevent and control potential risks that may affect the sustainable development of the Group, the Board Committee continues to play an important role in daily operations. Supervise and guide, supervise management and various functional departments to regularly carry out sustainable development-related risk identification, assessment and control, and regularly Report and make recommendations to the Board of Directors on identification results and response measures. The Group incorporates risks related to sustainable development into the overall risk management system as an important part of risk management. Oversight in the board of directors Under the current situation, the Group continues to improve its internal control and risk management system, strengthen risk prevention and control capabilities, and ensure that sustainable development risks are effectively understood. Don't worry about actual control. At the same time, the Group also continues to pay attention to potential opportunities brought by sustainable development trends, including green technology development, market Changes in demand and increased environmental awareness among consumers, etc., and incorporate relevant opportunities into strategic research and decision-making considerations to promote the Group's long-term stability healthy development.

Sustainability work execution ESG ESG ESG The Group has established a working group, which is responsible for promoting the sustainable development of the Group under the guidance of the Board Committee and the Management Committee. specific implementation and execution of development strategies and related projects to improve overall performance in the environmental, social and governance fields.

Important sustainable development issues The Group has established a transparent and efficient stakeholder communication mechanism to regularly identify the key concerns of stakeholders in terms of sustainable development. Make sure you understand their demands and expectations in a timely manner. Develop corresponding management strategies and action measures for sustainable development issues of high importance, and Continuously improve management effectiveness through regular reviews and evaluations to respond to and meet stakeholder expectations.

During the reporting period, the Group further improved the identification and analysis methods of important issues, and carried out the work from the two dimensions of financial importance and impact importance. The relevant content of the assessment is detailed below.

2025 Environmental, Social and Governance (ESG) and Sustainability Report

corporate governance

1.1.3 stakeholder engagement The Group adopts diversified communication methods to proactively communicate with governments and regulatory authorities, investors, customers, the public and media, employees, suppliers, and society. Maintain regular communication with key stakeholders such as districts and non-governmental organizations, and timely share the Group’s medium and long-term strategic plans and sustainable development progress. Through continuous interaction and in-depth communication with all parties, we systematically collect and fully understand stakeholders’ opinions on the sustainable development of the Group. development focus, expectations and demands, and incorporate relevant feedback into an important reference for management optimization and strategic improvement to promote continuous improvement

The Group's sustainable development management level and comprehensive performance.

Stakeholder identification Main sustainable development issues of concern Stakeholder communication channels/company feedback methods

Compliance Operation Policy Guidance Government and regulatory authorities Pay taxes in accordance with the law Daily information transfer and official document exchanges R&D Innovation Statutory Information Submission and Public Disclosure Health Accessibility Accept on-site inspections, audits and inspections

Anti-corruption Participate in policy discussions and industry standard formulation Apply for and participate in various government-led projects Report acceptance and processing through compliance channels

Corporate Governance and Compliance Operations Convene Shareholders’ Meeting investor Financial performance and growth potential Organize investor visits and surveys Information Disclosure and Transparency Organize online/offline roadshows Risk identification and management Participate in domestic and overseas strategy meetings Long-term Value and Shareholder Returns Hosting Investor Open Day Hold performance briefing meeting Establish hotline/email/website and other feedback platforms

Customer Product Quality and Safety Customer Satisfaction Survey Medical Service Quality Complaint Response Handling Responsible marketing to maintain a good doctor-patient relationship Customer privacy protection and information security Product quality and security information collection

Public and Media Information Disclosure Continue to improve and implement the information disclosure system Establish an effective media communication mechanism Through the company’s official website, officially certified social media and other self-owned platforms Taiwan, promptly release information that should be made public

2025 4 e 700 Note: In 2019, the Group held performance briefing meetings several times, responded to investor questions through the Shanghai Stock Exchange interactive platform, investor hotline/email and other channels, and conducted/participated in on-site surveys (see

(visits), online/telephone roadshows, and domestic and overseas strategies will exceed the number of events. 18 Innovation for Good Health Continuous innovation and enjoyment of health

corporate governance

Stakeholder identification Main sustainable development issues of concern Stakeholder communication channels/company feedback methods

Employee Rights and Welfare Trade Unions and Employee Representative Conferences

Training and Development Performance Appraisal Communication Occupational Health and Safety Complaints and Feedback employee satisfaction survey

Supplier Responsible Procurement Improvement System Integrity performance bidding meeting Win-win cooperation, research and visits

Fair and transparent communication and cooperation Audit and Assessment

Community and community contribution Participate in community service NGO Public Welfare Activities Organize and participate in social welfare activities Sustainable supply chain Join the Supply Chain Cooperation Organization Environmental risk management, energy conservation, emission reduction, pollutant emission control

2025 Environmental, Social and Governance (ESG) and Sustainability Report

corporate governance

1.1.4 ESG Analysis of important issues ESG In order to fully respond to the challenges that may arise from changes in internal and external factors, the Group regularly identifies key issues that it needs to pay attention to. 14 — GRI question. We follow the "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. Sustainability Report (Trial)" and the standards Accurately identify sustainable development issues that may have financial importance and impact on the Group, establish an issue database and carry out dual important sexual assessment. We not only pay attention to the potential impact of each issue on the financial status of the Group, but also pay attention to the impact of the Group’s management and performance on the corresponding issues. Influence from external society or related parties. By comprehensively considering the two dimensions of financial importance and impact importance of each issue, we identify and evaluate and rank the importance of issues. In the process of issue identification and importance assessment, we actively communicate with internal and external stakeholders Carry out communication, fully consider the opinions of key stakeholders, and finalize the matrix of important issues, and the board of directors will make the annual determination results for discussion and approval. ESG We have established and solidified the issue importance analysis process, and actively carried out the identification and impact assessment of important issues:

Identification of important issues Assessment and ranking of important issues

Based on business operations and based on expert opinions, peer experience, feedback from stakeholders such as management, investors and employees, Prioritize issues of importance based on changes in the internal and external environment. ation, refer to regulations for requirements, industry standards, etc. Impact materiality: Financial materiality: • • The importance of the positive and negative financial effects depends on the importance of the positive and negative financial effects Stakeholder consultation construction scale, scope and possibilities. Depends on the continuity of resource use, on the sustainability of • The importance of identifying potential negative impacts depends on the dependence of the impact on the production and operation relationships. ESG • important issues. Severity, Scope, Likelihood and Irreversibility Importance of setting thresholds to assess financial impact Savior. nature and prioritize issues of importance. • Set thresholds to assess the significance of the impact, and rank the issues of importance. ESG Fosun Pharma Issue Importance Analysis Process

20 Innovation for Good Health Continuous innovation and enjoyment of health

corporate governance

Based on the above steps, we have reviewed the "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. Sustainability Report (Trial)" 21 18 Each issue was analyzed one by one, and the issues were sorted out and integrated based on the actual operation conditions. Finally, a total of 10 issues that were critical to the Group were identified. 1,2,3 4 Important sustainable development issues, one of which involves issues of dual importance, including quality management, environmental management, climate response climate change and innovative research and development. We fully recognize the impact of important issues on our business development and the impact of their management on the economy, society and environment. coming influence. We have established management strategies for these important issues and continuously improved our own management level to better respond to and mitigate potential risks. Internal and external risks that may affect corporate operations and stakeholders. The specific order of topics is shown in the figure below: very high Quality management Yes Innovative research and development by Anti-commercial bribery and anti-corruption economy environmental management ︑ Stakeholder participation social contribution Social response to climate change Meeting Sustainable Supply Chain and Rural revitalization focuses on talents ring Information Security and Privacy Protection environment Shadow Anti-unfair competition Impact on clinical drug ethics of heavy want sex Circular Economy Corporate Governance Issues environmental issues Biodiversity and biodiversity conservation social issues medium very high financial importance to the company 2025 Fosun Pharma’s Annual Important Issues Matrix

1 300 50% Note: As of the end of the reporting period, the balance of the Group's accounts payable (including notes payable) did not exceed RMB 100 million, and its proportion to total assets did not exceed . The company has been listed in the National Enterprise Credit Information Disclosure There is no information on overdue payments to small and medium-sized enterprises in the system, so there is no "equal treatment of small and medium-sized enterprises" issue. During the reporting period, the Group did not engage in “due diligence” related to sustainable development, so it did not establish "Due Diligence" Issue. For details of the relevant content index, please see Appendix II of this report.

Note: The topic of "Coping with Climate Change" already includes content related to "Energy Utilization", and "Environmental Management" includes content related to "Environmental Compliance Management, Pollutant Discharge, Waste Treatment, and Water Utilization".

Note: Based on the Group's self-assessment, "circular economy" has not yet been included as an important issue.

2025 Environmental, Social and Governance (ESG) and Sustainability Report

corporate governance

1.2 Risk management and control 1.2.1 Risk prevention and control structure

Comprehensive risk management and control can help improve an enterprise's business capabilities and enable it to calmly respond to various changes and uncertainties in the external environment. Therefore, it is crucial for the Group to establish and continuously optimize the risk prevention and control structure. Through layer-by-layer management and control, we can effectively reduce risk insurance, reduce potential economic losses, and lay a solid foundation for long-term sustainable operations and success.

• Responsible for the establishment, improvement and effective implementation of internal controls board of directors

• Supervise the establishment and implementation of internal controls, including the effectiveness of internal control implementation and internal control Audit Committee Self-Assessment